WHO Issues Landmark Recommendations for RSV Prevention in Infants
Table of Contents
The global health body is urging widespread adoption of strategies to protect newborns from respiratory syncytial virus.
GENEVA – 2025/05/31 02:02:19 – The World Health Organization (WHO) has released its first-ever position paper on immunization products aimed at protecting infants from Respiratory Syncytial Virus (RSV). This thorough document outlines recommendations for maternal vaccination and the use of monoclonal antibodies to safeguard newborns against the virus, which poses a notable threat to infant health worldwide.
The WHO’s recommendations emphasize the importance of both maternal RSV vaccination and the governance of monoclonal antibodies as key strategies in preventing severe RSV infections in infants. These interventions are notably crucial in the lead-up to the 2025-2026 winter season, when RSV cases are expected to surge.
Global Experts Convene to Discuss RSV prevention Strategies
In related news, international and regional experts recently gathered at the Pfizer MERA Maternal Immunization Summit to discuss RSV prevention strategies. The summit focused on maternal immunization, infant protection, and clinical considerations for the upcoming year. Discussions centered on optimizing vaccination strategies to protect infants and address the clinical challenges associated with RSV.
“The WHO’s recommendations emphasize the importance of both maternal RSV vaccination and the administration of monoclonal antibodies.”
The WHO’s call for widespread maternal vaccination and the use of monoclonal antibodies represents a significant step forward in global efforts to combat RSV. By implementing these strategies, healthcare providers can substantially reduce the burden of RSV on infants and healthcare systems.
Implications for the 2025-2026 Winter Season
As the 2025-2026 winter season approaches, healthcare providers are urged to prioritize RSV prevention strategies. The WHO’s recommendations provide a framework for implementing effective interventions, including maternal vaccination programs and the administration of monoclonal antibodies to at-risk infants. By taking proactive measures, healthcare systems can mitigate the impact of RSV and protect vulnerable populations.
Frequently Asked Questions About RSV
- What is RSV?
- RSV stands for Respiratory Syncytial Virus. It is a common virus that causes infections of the lungs and respiratory tract.
- How is RSV spread?
- RSV is spread through droplets when someone coughs or sneezes, direct contact with the virus on surfaces, or through close contact with an infected person.
- What are the symptoms of RSV?
- Symptoms of RSV can include runny nose, fever, cough, wheezing, and difficulty breathing. In severe cases, it can lead to bronchiolitis or pneumonia.
- How can I protect my baby from RSV?
- You can protect your baby by practicing good hygiene, avoiding close contact with sick individuals, and considering maternal RSV vaccination or monoclonal antibody prophylaxis.
- Is there a treatment for RSV?
- Treatment for RSV typically involves supportive care,such as managing fever and ensuring adequate hydration. In severe cases, hospitalization and respiratory support may be necesary.
